Clinical Trials on Virus Disease

Total 378970 results

The University of Hong Kong

Completed

Risk of Hepatitis B Reactivation After Bone Marrow Transplantation With Prior Hepatitis B Virus (HBV) Exposure

Exposure to Hepatitis B Virus

Hong Kong
University Hospital, Limoges

Recruiting

NK Cell Deregulation in HBV Patients (LiNKeB)

Hepatitis B Virus

France
Centre Hospitalier Universitaire, Amiens

Completed

Mutations of the Pre-core Region of Hepatite B Virus (HBV) (HEPATITEB)

Hepatitis B Virus
Ablynx

Completed

A Multicentre Study in Otherwise Healthy Infants and Toddlers Hospitalised For and Diagnosed With RSV Lower Respiratory Tract Infection to Evaluate the Safety, Tolerability, and Clinical Activity of ALX-0171

Respiratory Syncytial Virus Infection

Australia, Belgium, Bulgaria, Estonia, Hungary, Israel, Latvia, Malaysia, Philippines, Poland, Slovakia, Spain, Thailand, United Kingdom
Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical...

Completed

The Relationship Between Vitamin D and Hepatitis B Virus Replication

Vitamin D and Hepatitis B Virus

Taiwan
The Methodist Hospital Research Institute
Grifols Biologicals, LLC

Completed

Improving Adherence to Rabies PEP Guideline Recommendations

Rabies | Rabies Human | Rabies Virus Infection

United States
GlaxoSmithKline

Recruiting

A Follow-up Study to Describe the Safety of Study Participants Who Received RSVPreF3 Maternal Vaccination (Any Dose) or Controls From Previous RSV MAT Studies During Any Pregnancy Conceived Post Vaccination/Control

Respiratory Syncytial Virus Infections

United States, Australia, Italy, Spain, Belgium, Korea, Republic of, France, Canada, Finland, Taiwan, Thailand, Brazil, India, New Zealand, Germany, South Africa, Colombia, Panama, Philippines, Argentina, Bangladesh, Dominican Republic and more
Pfizer

Completed

A Study to Learn About Effect of Sisunatovir in Healthy Adult Male Participants

Respiratory Syncytial Virus Infections

United States
GlaxoSmithKline

Terminated

A Phase III Double-blind Study to Assess Safety and Efficacy of an RSV Maternal Unadjuvanted Vaccine, in Pregnant Women and Infants Born to Vaccinated Mothers (GRACE)

Respiratory Syncytial Virus Infections

United States, Australia, France, Finland, Taiwan, Spain, Philippines, Mexico, Belgium, Italy, Panama, New Zealand, Thailand, Brazil, Canada, India, Colombia, Korea, Republic of, United Kingdom, South Africa, Argentina, Bangladesh, Dominican... and more
GlaxoSmithKline

Terminated

A Study on the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine, in High Risk Pregnant Women Aged 15 to 49 Years and Infants Born to the Vaccinated Mothers

Respiratory Syncytial Virus Infections

United States, Spain, Brazil, Canada, Finland, India, Italy, Panama, South Africa
GlaxoSmithKline

Active, not recruiting

Immunogenicity, Safety, Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above

Respiratory Syncytial Virus Infections

United States, Finland, Germany, Japan, Taiwan
Bavarian Nordic

Completed

MVA-BN-RSV Vaccine Trial

Respiratory Syncytial Virus Infections

United States, Germany
GlaxoSmithKline

Completed

A Study of Outcomes and Events of Interest in Pregnant Women, Neonates and Infants and of RSV Surveillance (PEPNI)

Respiratory Syncytial Virus Infections

Philippines, Mexico, Thailand, Brazil, Colombia, Panama, South Africa, Argentina, Bangladesh, Malaysia
GlaxoSmithKline

Completed

Extension Study to Evaluate the Safety and Immunogenicity of a Revaccination Dose of the RSVPreF3 OA Investigational Vaccine in Adults 60 Years and Older Who Participated in the RSV OA=ADJ-002 Study

Respiratory Syncytial Virus Infections

United States, Belgium
Janssen Research & Development, LLC

Completed

A Study to Explore the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of JNJ-53718678 at Two Dose Levels in Non-Hospitalized Adult Participants Infected With Respiratory Syncytial Virus

Respiratory Syncytial Virus Infections

United States, Taiwan, Japan, Korea, Republic of, France, Mexico, Brazil, Sweden, Argentina, Ukraine, Canada, Spain, Germany, Poland, Belgium, Russian Federation, South Africa, Australia, Bulgaria
GlaxoSmithKline

Withdrawn

A Study of Safety, Reactogenicity and Immune Response of the Repeat Vaccination Against RSV When Given to Female Participants of 18-49 Years of Age During Their Subsequent Uncomplicated Pregnancy

Respiratory Syncytial Virus Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Infectivity, Safety, and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (D46/NS2/N/ΔM2-2-HindIII) in RSV-Seronegative Infants 6 to 24 Months of Age

Respiratory Syncytial Virus Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children

Respiratory Syncytial Virus Infections

United States
Meissa Vaccines, Inc.

Completed

Study of the Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seropositive Children

Respiratory Syncytial Virus Infections

United States
Meissa Vaccines, Inc.

Completed

Safety and Immune Response to an Investigational Vaccine Against Respiratory Syncytial Virus in Healthy Adults

Respiratory Syncytial Virus Infections

United States
Novavax
Bill and Melinda Gates Foundation

Completed

A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization

Respiratory Syncytial Virus Infections

United States, Argentina, Australia, Bangladesh, Chile, Mexico, New Zealand, Philippines, South Africa, Spain, United Kingdom
University of North Carolina, Chapel Hill
Centers for Disease Control and Prevention; American Cancer Society, Inc.; New... and other collaborators

Withdrawn

Quality Improvement Strategies to Increase Human Papillomavirus (HPV) Vaccination in Integrated Healthcare Delivery Systems

Human Papillomavirus Infection

United States
GlaxoSmithKline

Completed

A Study to Rank Different Dosages of Antigen of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3003891A), Based on Their Immune Response and Safety, When Administered to Healthy Adult Women

Respiratory Syncytial Virus Infections

Germany, Estonia, Belgium, France
Merck Sharp & Dohme LLC

Completed

A Study of V503 Given Concomitantly With Menactra™ and Adacel™ in 11 to 15 Year Olds (V503-005)

Human Papillomavirus Infection
National Institute of Allergy and Infectious Diseases...

Completed

Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (D46/NS2/N/ΔM2-2-HindIII) in RSV-Seronegative Infants and Children 6 to 24 Months of Age

Respiratory Syncytial Virus Infections

United States
GlaxoSmithKline

Completed

Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3003891A) in Healthy Women

Respiratory Syncytial Virus Infections

Belgium
Alios Biopharma Inc.

Completed

Study of Single and Multiple Doses of ALS-008176 in Healthy Volunteers

Respiratory Syncytial Virus Infections

France
Sanford Health

Completed

Prevalence of Human Papillomavirus in Men Living in the Northern Plains

Human Papillomavirus Infection

United States
MedImmune LLC

Completed

A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897 in Healthy Adults

Respiratory Syncytial Virus Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Immune Response to a Respiratory Syncytial Virus (RSV) Vaccine in Adults, RSV-Seropositive Children, and RSV-Seronegative Infants and Children

Respiratory Syncytial Virus Infections

United States
GlaxoSmithKline

Completed

An Observational Study on the Prevalence of Human Papillomavirus Types in Women in the Kingdom of Bahrain

Human Papillomavirus Infection

Bahrain
Respivert Ltd

Completed

RV568 - Viral Challenge With RSV

Respiratory Syncytial Virus Infections

United Kingdom
Alnylam Pharmaceuticals

Completed

Intranasal ALN-RSV01 Administered to Adult Volunteers Experimentally Inoculated With Respiratory Syncytial Virus

Respiratory Syncytial Virus Infections

United States
Merck Sharp & Dohme LLC

Completed

Efficacy and Tolerability Study of V501 in Japanese Males (V501-122)

Condyloma Acuminata | Anogenital Human Papilloma Virus Infection
Federal Budgetary Research Institution State Research...

Completed

Safety and Tolerability Study of the VAC∆6 Vaccine in Volunteers Aged 18-40 Years

Smallpox | Monkeypox | Cowpox | Vaccinia Virus Infection

Russian Federation
National Institute of Allergy and Infectious Diseases...
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Completed

A Study of the Safety and Effectiveness of a Chickenpox Vaccine in HIV-Infected Children

HIV Infections

United States
MedImmune LLC

Completed

Study to Evaluate the Safety of MEDI-534 Vaccine Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3) in Healthy Children

Healthy

United States
University of Sao Paulo

Completed

Sensorimotor Outcomes of Children Exposed to Foetal Zika Virus Infection

Zika Virus Infection

Brazil
University of Maryland, Baltimore
Gilead Sciences

Completed

Ledipasvir/Sofosbuvir for Hepatitis B Virus Infection (APOSTLE)

Hepatitis B

United States
Starna Therapeutics

Not yet recruiting

A Study to Describe the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine STR-V003 in Healthy Adults (STR-V003)

Respiratory Syncytial Virus Infections
Wuhan BravoVax Co., Ltd.
Novotech (Australia) Pty Limited; Shanghai BravoBio Co., Ltd.

Not yet recruiting

Phase I Clinical Trial of a Candidate HPV Vaccine

Human Papillomavirus Infection

Australia
National Institute of Allergy and Infectious Diseases...
Johns Hopkins Bloomberg School of Public Health

Active, not recruiting

Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in Infants and Children

Respiratory Syncytial Virus Infections

United States
GlaxoSmithKline

Completed

A Study to Assess the Safety, Reactogenicity and Immune Response of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3844766A) in Older Adults

Respiratory Syncytial Virus Infections

United States, Belgium
GlaxoSmithKline

Completed

Respiratory Syncytial Virus (RSV) Investigational Vaccine in Infants Aged 6 and 7 Months Likely to be Unexposed to RSV

Respiratory Syncytial Virus Infections

Finland, Spain, United Kingdom, United States, Thailand, Brazil, Canada, Panama, Italy, Colombia, Mexico, Poland, Turkey
GlaxoSmithKline

Completed

A Study to Test GlaxoSmithKline's (GSK) Respiratory Syncytial Virus RSV Candidate Vaccine's Safety and Immune Response in Japanese Older Adults

Respiratory Syncytial Virus Infections

Japan
Pontificia Universidad Catolica de Chile
Millennium Institute on Immunology and Immunotherapy; Comisión Nacional de...

Completed

A Study to Assess Safety, Tolerability and Immunogenicity of the Live Attenuated hRSV Vaccine rBCG-N-hRSV (EVA-VRS01)

Respiratory Syncytial Virus Infections

Chile
University of North Carolina, Chapel Hill
Centers for Disease Control and Prevention; New York State Department of Health and other collaborators

Completed

Quality Improvement Strategies to Increase Human Papillomavirus (HPV) Vaccination

Human Papillomavirus Infection

United States
National Institute of Allergy and Infectious Diseases...

Completed

Safety and Immunogenicity of the RSV D46cpΔM2-2 Vaccine in RSV-Seropositive Children and RSV-Seronegative Infants and Children

Respiratory Syncytial Virus Infections

United States
Pfizer

Completed

Pharmacokinetics and Safety of RV521 Formulations (C19007)

Respiratory Syncytial Virus Infections

United Kingdom
GlaxoSmithKline

Withdrawn

A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the GlaxoSmithKline (GSK) Biologicals' Respiratory Syncytial Virus (RSV) Investigational Vaccine (GSK3003891A) in Healthy Pregnant Women and Infants Born to Vaccinated Mothers

Respiratory Syncytial Virus Infections

Finland, United States, Spain

Clinical Trials on Virus Disease

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Argentina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations